|
Gene: NPL |
Gene summary for NPL |
Gene summary. |
Gene information | Species | Human | Gene symbol | NPL | Gene ID | 80896 |
Gene name | N-acetylneuraminate pyruvate lyase | |
Gene Alias | C112 | |
Cytomap | 1q25.3 | |
Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | Q9BXD5 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
80896 | NPL | LZE4T | Human | Esophagus | ESCC | 4.81e-15 | 4.73e-01 | 0.0811 |
80896 | NPL | LZE8T | Human | Esophagus | ESCC | 4.10e-06 | 1.99e-01 | 0.067 |
80896 | NPL | LZE24T | Human | Esophagus | ESCC | 2.30e-04 | 1.92e-01 | 0.0596 |
80896 | NPL | LZE21T | Human | Esophagus | ESCC | 3.18e-04 | 3.74e-01 | 0.0655 |
80896 | NPL | P1T-E | Human | Esophagus | ESCC | 2.73e-02 | 1.70e-01 | 0.0875 |
80896 | NPL | P2T-E | Human | Esophagus | ESCC | 1.41e-19 | 4.65e-01 | 0.1177 |
80896 | NPL | P4T-E | Human | Esophagus | ESCC | 5.71e-11 | 3.18e-01 | 0.1323 |
80896 | NPL | P5T-E | Human | Esophagus | ESCC | 6.56e-03 | 5.02e-03 | 0.1327 |
80896 | NPL | P8T-E | Human | Esophagus | ESCC | 1.42e-07 | 3.07e-02 | 0.0889 |
80896 | NPL | P9T-E | Human | Esophagus | ESCC | 9.28e-20 | 4.77e-01 | 0.1131 |
80896 | NPL | P11T-E | Human | Esophagus | ESCC | 2.23e-09 | 2.74e-01 | 0.1426 |
80896 | NPL | P15T-E | Human | Esophagus | ESCC | 4.75e-07 | 1.18e-01 | 0.1149 |
80896 | NPL | P20T-E | Human | Esophagus | ESCC | 8.76e-18 | 4.79e-01 | 0.1124 |
80896 | NPL | P21T-E | Human | Esophagus | ESCC | 1.45e-02 | 3.59e-02 | 0.1617 |
80896 | NPL | P22T-E | Human | Esophagus | ESCC | 7.73e-16 | 2.69e-01 | 0.1236 |
80896 | NPL | P23T-E | Human | Esophagus | ESCC | 1.37e-17 | 6.08e-01 | 0.108 |
80896 | NPL | P24T-E | Human | Esophagus | ESCC | 4.29e-05 | 1.29e-01 | 0.1287 |
80896 | NPL | P26T-E | Human | Esophagus | ESCC | 5.25e-20 | 5.07e-01 | 0.1276 |
80896 | NPL | P27T-E | Human | Esophagus | ESCC | 8.46e-10 | 1.97e-01 | 0.1055 |
80896 | NPL | P28T-E | Human | Esophagus | ESCC | 9.65e-13 | 3.04e-01 | 0.1149 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00096155 | Liver | Cirrhotic | response to virus | 126/4634 | 367/18723 | 2.10e-05 | 2.77e-04 | 126 |
GO:001604212 | Liver | Cirrhotic | lipid catabolic process | 112/4634 | 320/18723 | 2.31e-05 | 3.03e-04 | 112 |
GO:003286811 | Liver | Cirrhotic | response to insulin | 95/4634 | 264/18723 | 2.77e-05 | 3.54e-04 | 95 |
GO:001087611 | Liver | Cirrhotic | lipid localization | 147/4634 | 448/18723 | 6.24e-05 | 7.12e-04 | 147 |
GO:00011013 | Liver | Cirrhotic | response to acid chemical | 52/4634 | 135/18723 | 2.65e-04 | 2.36e-03 | 52 |
GO:00067202 | Liver | Cirrhotic | isoprenoid metabolic process | 46/4634 | 116/18723 | 2.71e-04 | 2.41e-03 | 46 |
GO:000686911 | Liver | Cirrhotic | lipid transport | 128/4634 | 398/18723 | 4.54e-04 | 3.69e-03 | 128 |
GO:00108831 | Liver | Cirrhotic | regulation of lipid storage | 26/4634 | 57/18723 | 4.79e-04 | 3.85e-03 | 26 |
GO:000664111 | Liver | Cirrhotic | triglyceride metabolic process | 40/4634 | 100/18723 | 5.36e-04 | 4.23e-03 | 40 |
GO:00432002 | Liver | Cirrhotic | response to amino acid | 45/4634 | 116/18723 | 5.54e-04 | 4.36e-03 | 45 |
GO:19004077 | Liver | Cirrhotic | regulation of cellular response to oxidative stress | 36/4634 | 89/18723 | 7.79e-04 | 5.73e-03 | 36 |
GO:00199151 | Liver | Cirrhotic | lipid storage | 35/4634 | 87/18723 | 1.03e-03 | 7.20e-03 | 35 |
GO:0010888 | Liver | Cirrhotic | negative regulation of lipid storage | 13/4634 | 23/18723 | 1.12e-03 | 7.70e-03 | 13 |
GO:00067212 | Liver | Cirrhotic | terpenoid metabolic process | 38/4634 | 97/18723 | 1.16e-03 | 7.89e-03 | 38 |
GO:0002832 | Liver | Cirrhotic | negative regulation of response to biotic stimulus | 41/4634 | 108/18723 | 1.56e-03 | 1.01e-02 | 41 |
GO:00066926 | Liver | Cirrhotic | prostanoid metabolic process | 22/4634 | 49/18723 | 1.64e-03 | 1.05e-02 | 22 |
GO:00066936 | Liver | Cirrhotic | prostaglandin metabolic process | 22/4634 | 49/18723 | 1.64e-03 | 1.05e-02 | 22 |
GO:003355911 | Liver | Cirrhotic | unsaturated fatty acid metabolic process | 43/4634 | 116/18723 | 2.09e-03 | 1.29e-02 | 43 |
GO:004244511 | Liver | Cirrhotic | hormone metabolic process | 73/4634 | 218/18723 | 2.22e-03 | 1.36e-02 | 73 |
GO:19059521 | Liver | Cirrhotic | regulation of lipid localization | 62/4634 | 181/18723 | 2.53e-03 | 1.51e-02 | 62 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa005202 | Esophagus | ESCC | Amino sugar and nucleotide sugar metabolism | 35/4205 | 49/8465 | 1.60e-03 | 4.88e-03 | 2.50e-03 | 35 |
hsa0052011 | Esophagus | ESCC | Amino sugar and nucleotide sugar metabolism | 35/4205 | 49/8465 | 1.60e-03 | 4.88e-03 | 2.50e-03 | 35 |
hsa00520 | Oral cavity | OSCC | Amino sugar and nucleotide sugar metabolism | 34/3704 | 49/8465 | 2.48e-04 | 8.08e-04 | 4.11e-04 | 34 |
hsa005201 | Oral cavity | OSCC | Amino sugar and nucleotide sugar metabolism | 34/3704 | 49/8465 | 2.48e-04 | 8.08e-04 | 4.11e-04 | 34 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NPL | SNV | Missense_Mutation | novel | c.225N>C | p.Lys75Asn | p.K75N | Q9BXD5 | protein_coding | deleterious(0.01) | possibly_damaging(0.622) | TCGA-LL-A441-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
NPL | insertion | Frame_Shift_Ins | novel | c.677dupA | p.Thr227AspfsTer9 | p.T227Dfs*9 | Q9BXD5 | protein_coding | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
NPL | SNV | Missense_Mutation | c.359C>T | p.Thr120Ile | p.T120I | Q9BXD5 | protein_coding | deleterious(0.01) | possibly_damaging(0.541) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
NPL | insertion | Frame_Shift_Ins | novel | c.677dupA | p.Thr227AspfsTer9 | p.T227Dfs*9 | Q9BXD5 | protein_coding | TCGA-EK-A2R9-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | ||
NPL | SNV | Missense_Mutation | c.883N>G | p.Ser295Gly | p.S295G | Q9BXD5 | protein_coding | tolerated(0.26) | benign(0.001) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
NPL | SNV | Missense_Mutation | novel | c.190C>T | p.Arg64Cys | p.R64C | Q9BXD5 | protein_coding | deleterious(0.01) | benign(0) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
NPL | SNV | Missense_Mutation | rs780412696 | c.569N>A | p.Arg190His | p.R190H | Q9BXD5 | protein_coding | tolerated(0.43) | benign(0.001) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
NPL | SNV | Missense_Mutation | novel | c.920N>A | p.Ser307Tyr | p.S307Y | Q9BXD5 | protein_coding | deleterious(0.04) | benign(0.058) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
NPL | SNV | Missense_Mutation | rs780412696 | c.569N>A | p.Arg190His | p.R190H | Q9BXD5 | protein_coding | tolerated(0.43) | benign(0.001) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
NPL | SNV | Missense_Mutation | rs139205081 | c.338N>T | p.Pro113Leu | p.P113L | Q9BXD5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A0GP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |